Worldwide, an estimated 1.5 million patients receive a cardiovascular implantable electronic device (CIED) such as a pacemaker or implanted defibrillator each year. However, in approximately 1% to 4% of cases, CIED patients develop an infection, potentially as a result of bacteria introduced at the time of the implant surgery.1,2
CIED procedure-related infections are associated with significant morbidity, mortality, and cost. According to recent research, these infections are linked to a greater than three-fold increase in death at 12 months and a disruption in therapy in more than one-third of patients.3
Furthermore, patients with an infection also may experience extended hospital stays (9 to 18 days on average) undergoing multiple procedures,3,4 impaired quality of life for six months,3 and they pay approximately $2,000 in out-of-pocket costs to treat the infection.3 Hospitals spend, on average, $56,000 to $83,000 to manage each infection,3-9 and reimbursement often does not cover all of a hospital’s costs.
As the COVID-19 pandemic continues to be a major health disruptor across our nation and around the world, reducing infections and hospital admissions are particularly important such that patients do not require supplemental care, and by extension, have reduced exposure for themselves and clinicians.